🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Exciting news! We entered into an evaluation and potential licensing agreement with BioCopy AG! BioCopy will test our TCR-mimic antibodies against promising intracellular TAAs for the development of next-generation oncological drugs: biocytogen.com/biocytogen-ent… #Collaboration

Join us at booth #2388 at #ASGCT2024 by American Society of Gene & Cell Therapy in Baltimore, MD from May 7-11! Explore our 100% guaranteed service & learn how our humanized models, disease models& pharmacology services can enhance your Cell &Gene Therapy! biocytogen.com/join-us-at-asg…

The IL-17 cytokine family plays diverse roles in immune regulation, inducing proinflammatory responses & allergic reactions by stimulating various immune signaling molecules. It promotes the production of cytokines, chemokines & prostaglandins from different cell types

contributing to inflammation. IL-17 misregulation is associated with psoriasis, autoimmune encephalitis, rheumatoid arthritis, asthma, lupus, and anti-tumor immunity. It is also essential for the function of T helper 17 cells. Check out our B-hIL17A Mice: biocytogen.com/products/human…

Attending PEGS Boston 2024 next week? Swing by Booth #23 & check out our poster on Thur, May 16th! We'll be presenting "Generation of a Fully Human Antibody Library &Novel Linker/Payload to Facilitate Development of Antibody-Drug Conjugates &Other Antibody-Based Therapeutics”!

Our Poster number is C017. You don't want to miss it! See you there! biocytogen.com/pegs-boston-20… #PEGSBoston #PEGS2024 #AntibodyTherapeutics #AntibodyLibrary #Biologics #preclinical #renbiologics #antibody #cancer #biotech #nanobody #adc #renmice

🌟 May 2024 Newsletter 🌟 Check out our New Mouse Models, Cell Lines, New Promotion and Upcoming events! biocytogen.com/newsletter/ #LatestUpdates #DontMissOut #newsletter #may2024 #mousemodel #humanizedmodel #innovation #immunotherapy #cancerresearch #cancertherapy

Sarcomas, the 2nd most common type of solid tumor affecting children&adolescents, encompasses about 100 distinct subtypes, originating from diverse tissues such as bone &muscle. Conventional treatment approaches often fall short, particularly in cases diagnosed at advanced stages

We have pioneered the development of monoclonal antibodies (mAbs) & TCR-mimic antibodies for TCRm-T cell therapy aimed at treating sarcomas. Download NY-ESO-1/HLA-A02 poster to learn more: biocytogen.com/posters/precli… #SarcomaResearch #Immunotherapy #antibodylibrary #renbiologics

Lung cancer, a primary contributor to cancer-related deaths, impacts millions globally. Biocytogen is pioneering the advancement of novel therapeutic options for non-small cell lung cancer (NSCLC) through the discovery of fully human monoclonal antibodies (mAbs) &bispecific ADCs

Our anti-PD-L1 mAb demonstrates robust blocking activity &in vivo efficacy, while our anti-TNFR2 mAb exhibits potent ADCC effect &agonist activity. Our TAA-targeting mAbs &novel bsADCs display high target affinity. Download our poster for more👉biocytogen.com/posters/festiv…

Day 2 at #PEGSboston! Swing by booth #23 for a chat and learn about our BioMice and Renbiologics assets, ranging from preclinical animal models and pharmacology evaluation services to antibody assets for licensing. biocytogen.com/pegs-boston-20… #PEGSBoston #PEGS2024 #AntibodyLibrary

🎗️With 2.3M new cases & 670K deaths yearly, breast cancer necessitates innovative solutions. Triple-negative breast Cancer (TNBC) presents formidable challenges, but our novel assets offer hope: ✔️Bispecific ADCs like BCG023 & BCG033 show promising efficacy in preclinical studies

✔️ Monoclonal antibodies (mAbs) against Nectin-4, FGFR2b, CEACAM6, and ROR1 exhibit high target affinity & species cross-reactivity. Catch our poster C017 at #PEGSBoston 2024 on May 16th or reach out for data &partnership opportunities: [email protected] #BreastCancer

CD47 is instrumental in cancer progression by aiding immune evasion, promoting angiogenesis & facilitating tumor cell survival & metastasis. Through its interaction with macrophage receptors, CD47 prevents the phagocytosis of cancer cells, enabling them to evade immune detection.

Additionally, CD47 signaling stimulates the formation of new blood vessels, supporting tumor growth and metastasis. Check out our B-hCD47 mice: biocytogen.com/products/human… #immunecheckpoint #invivo #therapeutics #immunotherapy #antitumortherapy #cancertherapy #cancerresearch

🧀🐭 Happy National Cheese Day from Biocytogen! 🐭🧀 Let's celebrate with a virtual slice of cheese for our mighty mice heroes! 🧀🐭 #NationalCheeseDay #Biocytogen #HumanizedMice #ScienceWithCheese #SayCheese #Biotech

🌞 Join Biocytogen for a Biotech Happy Hour at the Lighthouse Cafe in South San Francisco on June 12, 2024 from 3 p.m. to 7 p.m. Enjoy a complimentary drink, network with industry colleagues! Register here: ow.ly/A2Fu50SbPkg #Biotech #Networking #HappyHour

From Target to Therapeutics with Humanized Mouse Models by Yuan Tian link.medium.com/JJ1JVeNJGLb